Keyphrases
Advanced HIV Disease
19%
Africa
8%
AIDS-related Deaths
7%
AIDS/HIV
18%
AmBisome
8%
Amphotericin B
11%
Antigen Screening
31%
Antigen Test
8%
Antiretroviral Therapy
20%
CD4 Count
10%
Cerebrospinal Fluid
24%
Clinical Outcomes
7%
Clinical Trials
13%
Confidence Interval
6%
Cost-effectiveness
18%
COVID-19
31%
Cryptococcal Antigen
65%
Cryptococcal Antigenemia
28%
Cryptococcal Infection
8%
Cryptococcal Meningitis
78%
Cryptococcosis
12%
Cryptococcus
16%
Fluconazole
28%
Healthcare Workers
7%
High Dose
6%
Histoplasmosis
8%
HIV Patients
22%
HIV-associated
13%
Hydroxychloroquine
20%
Incremental Cost-effectiveness Ratio
6%
Induction Therapy
8%
Kampala Uganda
7%
Lateral Flow Assay
16%
Liposomal Amphotericin B
7%
Meningitis
33%
Non-HIV Cryptococcal Meningitis
13%
People Living with HIV (PLHIV)
12%
Point-of-care
6%
Pre-exposure Prophylaxis (PrEP)
11%
Preemptive Treatment
7%
Randomized Clinical Trial
10%
Randomized Trial
8%
Screening Program
13%
South Africa
8%
Sub-Saharan Africa
16%
Titer
11%
Tuberculous Meningitis
8%
Uganda
41%
Ugandan
16%
Xpert MTB
7%
Medicine and Dentistry
Amphotericin
12%
Amphotericin B Lipid Complex
6%
Antigen
28%
Antiretroviral Therapy
23%
Cerebrospinal Fluid
18%
Cerebrospinal Fluid Culture
5%
Clinical Trial
11%
Cluster Randomized Trial
5%
Cohort Effect
8%
Cost-Effectiveness Analysis
23%
COVID-19
17%
Cryptococcal Meningitis
73%
Cryptococcosis
11%
Diagnosis
17%
Diagnostic Performance
7%
Disease
14%
Drug Megadose
6%
Fluconazole
18%
Health Care Cost
21%
Human Immunodeficiency Virus
100%
Hydroxychloroquine
7%
Infection
19%
Lateral Flow Assay
21%
Lumbar Puncture
5%
Meningitis
39%
Outpatient
15%
Prevalence
15%
Randomized Clinical Trial
6%
Randomized Controlled Trial
6%
Screening
10%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Systematic Review
8%
Tuberculous Meningitis
6%